Regency Capital Management Inc. DE Makes New Investment in TransMedics Group, Inc. $TMDX

Regency Capital Management Inc. DE purchased a new position in shares of TransMedics Group, Inc. (NASDAQ:TMDX) during the 1st quarter, HoldingsChannel.com reports. The fund purchased 21,846 shares of the company’s stock, valued at approximately $2,172,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Royal Bank of Canada raised its stake in TransMedics Group by 47.9% during the first quarter. Royal Bank of Canada now owns 26,582 shares of the company’s stock worth $1,788,000 after purchasing an additional 8,604 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of TransMedics Group by 4.7% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,525 shares of the company’s stock valued at $1,314,000 after buying an additional 868 shares during the period. Goldman Sachs Group Inc. grew its stake in shares of TransMedics Group by 20.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 507,510 shares of the company’s stock valued at $34,145,000 after buying an additional 86,721 shares during the period. Russell Investments Group Ltd. grew its stake in shares of TransMedics Group by 13.5% in the 2nd quarter. Russell Investments Group Ltd. now owns 7,901 shares of the company’s stock valued at $1,059,000 after buying an additional 938 shares during the period. Finally, M&T Bank Corp acquired a new stake in shares of TransMedics Group during the 2nd quarter worth approximately $209,000. Institutional investors and hedge funds own 99.67% of the company’s stock.

Wall Street Analyst Weigh In

TMDX has been the topic of several analyst reports. Weiss Ratings reaffirmed a “hold (c)” rating on shares of TransMedics Group in a research report on Tuesday, June 9th. Piper Sandler cut their target price on TransMedics Group from $160.00 to $120.00 and set an “overweight” rating for the company in a research note on Wednesday, May 6th. Canaccord Genuity Group restated a “buy” rating and issued a $124.00 target price on shares of TransMedics Group in a research report on Tuesday, June 30th. UBS Group reaffirmed a “hold” rating on shares of TransMedics Group in a research note on Tuesday, May 26th. Finally, Wall Street Zen cut TransMedics Group from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Six analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, TransMedics Group has a consensus rating of “Hold” and an average target price of $134.50.

TransMedics Group Stock Performance

Shares of TransMedics Group stock opened at $75.38 on Thursday. The stock has a market capitalization of $2.61 billion, a price-to-earnings ratio of 17.13 and a beta of 1.89. The company has a debt-to-equity ratio of 1.70, a current ratio of 6.74 and a quick ratio of 6.19. The business has a 50-day moving average of $70.66 and a 200 day moving average of $105.14. TransMedics Group, Inc. has a 12 month low of $60.10 and a 12 month high of $156.00.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings results on Tuesday, May 5th. The company reported $0.30 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.32). The business had revenue of $173.93 million for the quarter, compared to analysts’ expectations of $174.44 million. TransMedics Group had a return on equity of 22.38% and a net margin of 27.04%.The firm’s revenue for the quarter was up 21.2% on a year-over-year basis. During the same quarter last year, the company earned $0.70 earnings per share. As a group, sell-side analysts forecast that TransMedics Group, Inc. will post 1.92 earnings per share for the current year.

Insider Buying and Selling at TransMedics Group

In related news, Director Thomas J. Gunderson sold 9,624 shares of the company’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $75.06, for a total transaction of $722,377.44. Following the sale, the director directly owned 16,642 shares of the company’s stock, valued at $1,249,148.52. This represents a 36.64% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 6.90% of the company’s stock.

TransMedics Group Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.